June 8, 2020 / 5:07 AM / a month ago

BRIEF-Bavarian Nordic Announces Topline Results From Phase 1 Clinical Trial Of Equine Encephalitis Virus Vaccine

June 8 (Reuters) - Bavarian Nordic A/S:

* REG-BAVARIAN NORDIC ANNOUNCES TOPLINE RESULTS FROM PHASE 1 CLINICAL TRIAL OF EQUINE ENCEPHALITIS VIRUS VACCINE

* REG-BAVARIAN NORDIC ANNOUNCES TOPLINE RESULTS FROM PHASE 1 CLINICAL TRIAL OF EQUINE ENCEPHALITIS VIRUS VACCINE

* DATA FROM STUDY SHOWED THAT VACCINE WAS WELL TOLERATED AND IMMUNOGENIC ACROSS ALL DOSE GROUPS

* CLINICALLY MEANINGFUL PHASE 1 DATA WARRANT FURTHER CLINICAL INVESTIGATION

* IS CURRENTLY IN PROCESS OF OBTAINING ADDITIONAL FUNDING FROM U.S. AUTHORITIES FOR FURTHER CLINICAL ADVANCEMENT OF VACCINE CANDIDATE

* MOST COMMON VACCINE-RELATED ADVERSE EVENT WAS INJECTION SITE PAIN Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below